IL6 and systemic sclerosis: Paclitaxel and docetaxel can lead to an increase in serum IL-6 levels [93], which can mediate endothelial cell activation and apoptosis in patients with systemic sclerosis (SSc) and participate in the early stages of SSc development [94].